株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

抗レトロウイルス薬の世界市場の分析:機会と予測

Global Antiretroviral Drugs Market: Analysis By Drug Type, By Region, By Country, Drug Forecast : Opportunities and Forecast - By Region, By Country

発行 Azoth Analytics 商品コード 817527
出版日 ページ情報 英文 230 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.28円で換算しております。
Back to Top
抗レトロウイルス薬の世界市場の分析:機会と予測 Global Antiretroviral Drugs Market: Analysis By Drug Type, By Region, By Country, Drug Forecast : Opportunities and Forecast - By Region, By Country
出版日: 2019年03月31日 ページ情報: 英文 230 Pages
概要

当レポートでは、世界の抗レトロウイルス薬市場について調査分析し、統計と情報 (市場規模・シェア・成長要因) のほか、新興動向、主要促進要因、課題と機会、主要企業について、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 戦略的提言

第4章 抗レトロウイルス薬:製品の見通し

第5章 世界の抗レトロウイルス薬市場:成長率と予測

  • 金額別 (実績)
  • 金額別 (予測)

第6章 世界の抗レトロウイルス薬市場:セグメント別分析

  • 薬剤タイプ別:内訳
  • 多クラス混合製品
  • NRTI
  • NNRTI
  • プロテアーゼ阻害剤
  • その他
  • 市場の魅力:薬剤タイプ別
  • 世界市場:薬剤予測

第7章 世界の抗レトロウイルス薬市場:地域別分析

  • 地域別:内訳

第8章 北米の抗レトロウイルス薬市場:成長率と予測

第9章 欧州の抗レトロウイルス薬市場:成長率と予測

第10章 アジア太平洋地域の抗レトロウイルス薬市場:成長率と予測

第11章 その他の地域の抗レトロウイルス薬市場:成長率と予測

第12章 世界の抗レトロウイルス薬市場:市場力学

第13章 ファイブフォース分析

第14章 SWOT分析

第15章 企業プロファイル

  • Gilead Sciences
  • ViiV Healthcare
  • Bristol-Myer Squibb
  • AbbVie Inc.
  • Boehringer-Ingelheim
  • Johnson and Johnson
  • Merck & Co.
  • CIPLA
図表

List of Figures

  • Figure 1: Global Antiretroviral Drugs Market Size, By Value, 2013-2017 (USD Million)
  • Figure 2: Global HIV, AIDS Prevalence, 2013-2017, Millions
  • Figure 3: Global HIV Prevalence, By Population Group, 2017
  • Figure 4: Global HIV Prevalence By Region, 2017
  • Figure 5: Change in the HIV Infection Prevalence in Between 2010 & 2017
  • Figure 6: Global HIV Treatment Status, 2017
  • Figure 7: HIV Patients on ARV Treatment, 2013-2017 (% of Total Patients)
  • Figure 8: Comparison on Number of HIV with Number of Patients on ART, 2013-2017, (Million)
  • Figure 9: HIV Related Deaths, 2013-2017, (Million)
  • Figure 10: INSTI Based Regimen, 2018 ( USD Million)
  • Figure 11: harmaceutical Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region
  • Figure 12: HIV Funding In Low and Middle Income Countries, 2013-2017, (USD Billions)
  • Figure 13: PEPFAR Funding, 2015-2017 (USD Millions)
  • Figure 14: HIV Prevalence Region Wise, 2017 (Millions)
  • Figure 15: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %)
  • Figure 16: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
  • Figure 17: Expected Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 18: Global Aged Population(Above 65), By Country, 2017 (% of total)
  • Figure 19: Global Aged Population (Above 65), 2013-2017 (% of total)
  • Figure 20: HIV DAYLs Per 100000, Global, All Sex, All Age, 2013-2017
  • Figure 21: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 22: Global Expected Healthcare Industry Outlook
  • Figure 23: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 24: Global Antiretroviral Drugs Market Size, By Value, Forecast, 2018-2023 (USD Million)
  • Figure 25: Global Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 26: Global Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 27: Global Multi-Class Drugs Combination Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 28: Global Multi-Class Drugs Combination Antiretroviral Market, By Value, 2018-2023(USD Million)
  • Figure 29: Global NRTI Antiretroviral Drugs Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 30: Global NRTI Antiretroviral Drugs Drugs Market, 2018-2023(USD Million)
  • Figure 31: Global NNRTI Antiretroviral Drugs Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 32: Global NNRTI Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 33: Global Protease Inhibitors Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 34: Global Protease Inhibitors Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 35: Global Other Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 36: Global Other Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 37: Global Market Attractiveness, By Product Type, 2023F
  • Figure 38: Stribild®, Sales, 2013-2023F, (USD Million)
  • Figure 39: Triumeq®, Sales, 2014-2023F , (USD Million)
  • Figure 40: Genvoya®, Sales, 2016-2023F, (USD Million)
  • Figure 41: Odefsey®, 2016-2023F, (USD Million)
  • Figure 42: Juluca®, Sales, 2017-2023F, (USD Million)
  • Figure 43: Biktarvy®, Sales, 2018-2023F, (USD Million)
  • Figure 44: Epzicom/ Kivexa®, Sales, 2013-2023F, (USD Million)
  • Figure 45: EDURANT®, Sales, 2013-2023F, (USD Million)
  • Figure 46: PREZISTA/PREZCOBIX® /REZOLSTA®, Sales, 2013-2023F, (USD Million)
  • Figure 47: Tivicay®, Sales, 2013-2023F, (USD Million)
  • Figure 48: Isentress/Isentress HD 2013-2023F, (USD Million)
  • Figure 49: Selzentry® / Celsentri®2013-2023F, (USD Million)
  • Figure 50: Global Antiretroviral Drugs Market Size, By Region, 2017 (%)
  • Figure 51: Global Antiretroviral Drugs Market Size, By Region, 2023F (%)
  • Figure 52: North America Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 53: North America, HIV Prevalence, 2013-2017
  • Figure 54: North America HIV Incidence vs HIV Related Deaths,2013-2017
  • Figure 55: United States Spending on Medicines, 2013-2017 (In USD Billion)
  • Figure 56: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion)
  • Figure 57: North America population aged 65 and above, 2013-2017 (% of total)
  • Figure 58: North America Healthcare Cost Per Capita, 2017 (USD)
  • Figure 59: North America GDP per Capita, 2013-2017 (USD)
  • Figure 60: North America Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 61: North America Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 62: North America Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 63: North America Antiretroviral Drugs Market,By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 64: North America Antiretroviral Drugs Market,By Drug Type , By Value, 2018-2023(USD Million)
  • Figure 65: North America Antiretroviral Drugs Market Size, By Countries, 2017 (%)
  • Figure 66: North America Antiretroviral Drugs Market Size, By Countries, 2023F (%)
  • Figure 67: USA Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 68: USA Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 69: HIV Prevalence, USA, 2013-2017, (Millions)
  • Figure 70: New HIV Cases, By Age, USA, 2017
  • Figure 71: HIV Prevalence, USA, By Ethnicity, 2016
  • Figure 72: New HIV Cases, By States, USA, 2017
  • Figure 73: HIV Related Statistics, USA, 2017
  • Figure 74: HIV Funding, USA, 2017, USD Billion
  • Figure 75: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
  • Figure 76: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion)
  • Figure 77: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million)
  • Figure 78: U.S., Population ages 65 and above, 2013-2017 (% of total)
  • Figure 79: U.S., Population ages 65 and above, Forecast (In Millions)
  • Figure 80: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 81: U.S., GDP (Current USD), 2013-2017 (In USD Trillion)
  • Figure 82: USA Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 83: USA Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 84: USA Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 85: USA Antiretroviral Drugs Market,By Drug Type, By Value, 2018-2023(USD Million)
  • Figure 86: Canada Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 87: Canada Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 88: Canada HIV Prevalence, 2013-2017
  • Figure 89: Canada, HIV Related Statistics, 2017
  • Figure 90: Canada, HIV Prevalence By Sex & Ethnicity
  • Figure 91: Number of Retail Pharmacies in Canada, 2013-2017
  • Figure 92: Number of Hospitals Establishments in Canada, By Province, 2015
  • Figure 93: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %)
  • Figure 94: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD)
  • Figure 95: Canada, Population ages 65 and above, 2012-2017 (% of total)
  • Figure 96: anada Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 97: Canada Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 98: Canada Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 99: Europe Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 100: Europe, HIV Prevalence, 2013-2017
  • Figure 101: European Union, Antiretroviral Drugs Therapy Coverage, 2013-2017, (% of Total Patient Population)
  • Figure 102: Percentage of new HIV diagnoses, By country and Sge group, EU/EEA, 2017
  • Figure 103: Proportion of New HIV Diagnoses, By Country and transmission, EU/EEA, 2017
  • Figure 104: Europe Health Expenditure, By Select Country, 2016 (% of GDP)
  • Figure 105: Europe Population ages 65 years and above (% of total population), 2013-17
  • Figure 106: Europe Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 107: Europe Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 108: Europe Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 109: Europe Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 110: Europe Antiretroviral Drugs Market Size, By Countries, 2017 (%)
  • Figure 111: Europe Antiretroviral Drugs Market Size, By Countries, 2023F (%)
  • Figure 112: Germany Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 113: Germany Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 114: Germany, HIV Prevalence, 2013-2017
  • Figure 115: Germany, ARV Coverage, (% of Total Patients)
  • Figure 116: Germany, Healthcare Related Statistics, 2017
  • Figure 117: Germany, Population ages 65 and above, 2012-2017 (% total)
  • Figure 118: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 119: Germany Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 120: Germany Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 121: Germany Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 122: France Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 123: France Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 124: France, HIV Prevalence, 2013-2017
  • Figure 125: France, HIV Prevalence, 2017, By Sex, (% of Total)
  • Figure 126: France, Healthcare Infrastructure Related Statistics
  • Figure 127: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter),
  • Figure 128: France, ART Coverage, 2013-2017, (% of Total Patients)
  • Figure 129: France, ART Coverage, % of Total, By Sex, 2017
  • Figure 130: France, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 131: France, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 132: France Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 133: France Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 134: France Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 135: U.K Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 136: U.K Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 137: U.K, HIV Prevalence, 2013-2017
  • Figure 138: UK, HIV Treatment Status, 2017
  • Figure 139: UK, HIV Related Statistics, 2017
  • Figure 140: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD)
  • Figure 141: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 142: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 143: U.K Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 144: U.K Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 145: U.K Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 146: Italy Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 147: Italy Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 148: Italy, HIV Prevalence, 2013-2017
  • Figure 149: Italy, ART Coverage, 2013-2017
  • Figure 150: Italy, AIDS Prevalence, By Age, 2017
  • Figure 151: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD)
  • Figure 152: Italy, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 153: Italy, Healthcare Infrastructure Related Statistics
  • Figure 154: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 155: Italy Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 156: Italy Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 157: Italy Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 158: APAC Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 159: Indonesia, HIV Prevalence, 2013-2017
  • Figure 160: APAC, HIV Prevalence, By Selected Countries, 2017
  • Figure 161: APAC, HIV Treatment Status, 2017
  • Figure 162: APAC, Incidence vs Death Ratio, By Selected Countries,2017
  • Figure 163: China, Pharmaceuticals Industry Revenue (USD Billion)
  • Figure 164: Japan, Total Drugs Market, 2013-2017, USD Billion
  • Figure 165: India Pharma Market, 2015-2017, (USD Billion)
  • Figure 166: GDP Per Capita in APAC, By Select Country, 2016 (In USD)
  • Figure 167: Population ages 65 and above, By Select Country, 2017 (% of total)
  • Figure 168: APAC Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 169: APAC Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 170: APAC Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 171: APAC Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 172: APAC Antiretroviral Drugs Market Size, By Countries, 2017 (%)
  • Figure 173: APAC Antiretroviral Drugs Market Size, By Countries, 2023F (%)
  • Figure 174: China Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 175: China Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 176: China, HIV Prevalence, 2013-2017
  • Figure 177: China, HIV Related Deaths, 2013-2016
  • Figure 178: China, GDP Growth Per Year, 2015-2019 (In %)
  • Figure 179: China, Share of Urban Population, 2012-2017 (In %)
  • Figure 180: China, Total Population, 2013-2021F (In Billion)
  • Figure 181: China Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 182: China Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 183: China Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 184: Japan Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 185: Japan Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 186: Japan Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 187: Japan, HIV Prevalence, 2013-2017
  • Figure 188: Japan, Medical & HIV Facilities Outlook
  • Figure 189: Japan Healthcare Expenditure Outlook (%)
  • Figure 190: Japan, HIV DALYs Rate, (Per 100000), 2013- 2017
  • Figure 191: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 192: Japan Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 193: Japan Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 194: Japan Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 195: India Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 196: India Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 197: India, HIV Prevalence, 2013-2017
  • Figure 198: India, ART Coverage, (% of Patient Population)
  • Figure 199: India, HIV Treatment Status, 2017
  • Figure 200: India, Diseases & Medical Industry Outlook
  • Figure 201: India, Population ages 65 and above, 2013-2017
  • Figure 202: India, Total Population, 2013-2023F (In Billion)
  • Figure 203: Pharma Export From India Market, 2013-2017, (USD Billion)
  • Figure 204: India Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 205: India Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 206: India Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 207: ROW Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 208: ROW, HIV Prevalence, By Country, 2013-2017
  • Figure 209: ROW, ART Coverage, 2013-2017, (% of Total Patient Population), By Selected Countries
  • Figure 210: ROW, HIV DALYs, Rate Per 100000 Population, By Selected Countries, 2017
  • Figure 211: Middle East and North Africa, Population ages 65 and above (% of total)
  • Figure 212: Latin America and Caribbean, Population ages 65 and above 2012-2017(% of total)
  • Figure 213: GDP Per Capita in ROW, By Select Country, 2013 (In USD)
  • Figure 214: GDP Per Capita in ROW, By Select Country, 2017 (In USD)
  • Figure 215: ROW Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 216: ROW Antiretroviral Drugs Market, By Value, 2018-2023 (USD Million)
  • Figure 217: ROW Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 218: ROW Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 219: South Africa Antiretroviral Drugs Market, By Value, 2013-2017 (USD Million)
  • Figure 220: South Africa Antiretroviral Drugs Market, By Value, 2018-2023(USD Million)
  • Figure 221: South Africa, HIV Prevalence, 2013-2017
  • Figure 222: South Africa, HIV Prevalence, By Age, 2013-2017
  • Figure 223: South Africa, ART Coverage, 2013-2017, (% of Total)
  • Figure 224: South Africa, HIV Treatment Status, 2017
  • Figure 225: South Africa, Comparison Between Patients on ART and HIV Deaths, 2013-2017
  • Figure 226: South Africa, DALYs, (% of Life Years)
  • Figure 227: South Africa Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
  • Figure 228: South Africa Antiretroviral Drugs Market Size, By Drug Type, 2023F (%)
  • Figure 229: South Africa Antiretroviral Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million)
  • Figure 230: Gilead Sciences Inc., Net Sales, 2013-2017 (USD Million)
  • Figure 231: Gilead Sciences Inc., By Segments, 2017(%)
  • Figure 232: Gilead Sciences Inc., By Region, 2017(%)
  • Figure 233: Gilead Sciences Inc., ARV Drugs Patent Status, United States and Europe
  • Figure 234: GSK (ViiV Healthcare), Net HIV Drugs Sales, 2013-2017 (USD Million)
  • Figure 235: GSK (ViiV Healthcare), HIV Drugs Sales, By Drugs, 2017 (USD Million)
  • Figure 236: GSK (ViiV Healthcare), HIV Drugs Sales, By Geographic Region, (% of Total), 2017
  • Figure 237: GSK (ViiV Healthcare), HIV Drugs, Patent Status
  • Figure 238: Bristol-Myers Squibb, Net Sales, 2013-2017 (USD Million)
  • Figure 239: Bristol-Myers Squibb, By Region, 2017(%)
  • Figure 240: Bristol-Myers Squibb, Net Sales, By Segments, 2017 (USD Million)
  • Figure 241: AbbVie Inc., Net Sales, 2013-2017 (USD Million)
  • Figure 242: AbbVie Inc., Sales, By Region, 2017(%)
  • Figure 243: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million)
  • Figure 244: Boehringer-Ingelheim, By Segments, 2017(%)
  • Figure 245: Boehringer-Ingelheim, By Region, 2017(%)
  • Figure 246: Johnson & Johnson Pharmaceuticals, Net Sales, 2013-2017 (USD Million)
  • Figure 247: Johnson & Johnson Pharmaceuticals, ARV Drug Sales, 2015-2017 (USD Million)
  • Figure 248: Johnson & Johnson Pharmaceuticals, By Segments, 2017(%)
  • Figure 249: Johnson & Johnson Pharmaceuticals, By Region, 2017(%)
  • Figure 250: Merck & Co., Revenues 2013-2017(USD Million)
  • Figure 251: Merck & Co., Revenues, By Region, 2017(% of Total)
  • Figure 252: Merck & Co., Isentress Sales, 2015-2017(USD Million)
  • Figure 253: Cipla, Net Sales, 2013-2017 (USD Million)
  • Figure 254: Cipla, Sales, By Region, 2017(%)
  • Figure 255: Mylan, Net Sales, 2013-2017 (USD Million)
  • Figure 256: Mylan, By Region, 2017(%)

List of Tables

  • Table A: Different Types of Antiretroviral Drugs Drugs
  • Table B: ARV Regimen Priority Wise Recommendation in US and Europe, 2018
  • Table C: ARV Drugs in Development Phase
  • Table D: ARV Drugs Patent Status
  • Table E: Major ARV Drugs Brands, By Class
  • Table F: Product Benchmarking
目次

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of antiretroviral market. The report analyses the Antiretroviral Market By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others). The report analyses the antiretroviral market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes drug sales forecast for some antiretroviral drugs.

According to Azoth Analytics research report "Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa), Drug Forecast (2019 Edition): Forecast to 2023", the antiretroviral market is projected to display a robust growth represented by a CAGR of 4.70% during 2018 - 2023.

Over the recent years, Antiretroviral drugs market has been witnessing growth on account of several driving factors including growing prevalence of HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs with better efficacy. Moreover, factors such as growing medical spending, favorable steps by government of various countries, decreased cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population has been driving the market growth of antiretroviral drugs. In addition, increasing uptake of INSTI based regimens, increasing awareness regarding HIV care and treatment procedures, new drug launches, and improved R&D pipeline are anticipated to fuel the market growth in forecasted period. However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth.

In this research report, the market is segmented on the basis of drug type. By drug type, the multi-class drug combinations are predicted to hold their dominant position in the market, especially Gilead Sciences product Biktarvy and ViiV Healthcare product Triumeq are expected to give more traction to the market. Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017. The largest share of North America is attributed to high ART coverage rate and more emphasis towards prescribed branded drugs.

The report titled "Global Antiretroviral Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others), By Region (North America, Europe, Asia Pacific, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa), Drug Forecast (2019 Edition): Forecast to 2023" has covered and analysed the potential of antiretroviral drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the antiretroviral market. Additionally, the report also highlights market entry strategies for various companies across the globe along with drug sales forecast analysis.

Scope of the Report

Global Antiretroviral Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Antiretroviral Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.
  • Drug Sales Forecast:

Multi-Class Drugs Combination: Juluca®, Triumeq®, Genvoya®, Odefsey®, Stribild®, Biktarvy®.

Nucleoside Reverse Transcriptase Inhibitors: Epzicom®/ Kivexa®.

Non-Nucleoside Reverse Transcriptase Inhibitors: Edurant®.

Protease Inhibitors: PREZISTA ® /PREZCOBIX® /REZOLSTA ®.

Integrase Strand Transfer Inhibitors: Tivicay®, Isentress/Isentress HD®.

CCR5 Inhibitor: Selzentry®/ Celsentri®.

Regional Antiretroviral Drugs Market - North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Antiretroviral Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.

Country Analysis - U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Antiretroviral Drugs Market- Size, Growth, Forecast
  • Analysis By Drug Type - Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors, and Others.

Other Report Highlights

  • Product Sales Forecast.
  • Market Dynamics - Drivers and Restraints.
  • Market Trends.
  • Porter Five Forces Analysis.
  • SWOT Analysis.
  • Company Analysis - Gilead Sciences Inc., ViiV Healthcare, Bristol-Myers Squibb, AbbVie Inc., Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Cipla, Mylan.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Antiretroviral Drugs Products Outlook

5. Global Antiretroviral Drugs Market: Growth and Forecast

  • 5.1 By Value (2013-2017)
  • 5.2 By Value (2018-2023)

6. Global Antiretroviral Drugs Market: Segment Analysis

  • 6.1 Global Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
    • 6.1.1 Global Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
    • 6.1.2 Global Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
  • 6.2 Global Multi-Class Drugs Combination Market Size, By Value (2013-2023)
  • 6.3 Global NRTI Market Size, By Value (2013-2023)
  • 6.4 Global NNRTI Market Size, By Value (2013-2023)
  • 6.5 Global Protease Inhibitors Market Size, By Value (2013-2023)
  • 6.6 Global Other Antiretroviral Drugs Market Size, By Value (2013-2023)
  • 6.6 Global Antiretroviral Drugs: Market Attractiveness, By Drug Type
  • 6.7 Global Market: Drugs Forecast (Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, CCR5)

7. Global Antiretroviral Drugs Market: Regional Analysis

  • 7.1 Global Antiretroviral Drugs Market Size, By Region : Breakdown (%)
    • 7.1.1 Global Antiretroviral Drugs Market Size, By Region, 2017 (%)
    • 7.1.2 Global Antiretroviral Drugs Market Size, By Region, 2023 (%)

8. North America Antiretroviral Drugs Market: Growth and Forecast

  • 8.1 North America Antiretroviral Drugs Market: Segmental Analysis
  • 8.2 North America Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
    • 8.2.1 North America Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
    • 8.2.2 North America Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
  • 8.3 North America Multi-Class Drugs Combination Market Size, By Value (2013-2023)
  • 8.4 North America NRTI Market Size, By Value (2013-2023)
  • 8.5 North America NNRTI Market Size, By Value (2013-2023)
  • 8.6 North America Protease Inhibitors Market Size, By Value (2013-2023)
  • 8.7 North America Other Antiretroviral Drugs Market Size, By Value (2013-2023)
  • 8.9 North America Antiretroviral Drugs Market: Country Analysis (U.S and Canada)
    • 8.9.1 U.S Antiretroviral Drugs Market, By Value (2013-2023)
    • 8.9.2 U.S Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)
    • 8.9.3 Canada Antiretroviral Drugs Market, By Value (2013-2023)
    • 8.9.4 Canada Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

9. Europe Antiretroviral Drugs Market: Growth and Forecast

  • 9.1 Europe Antiretroviral Drugs Market: Segmental Analysis
  • 9.2 Europe Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
    • 9.1.2 Europe Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
    • 9.1.3 Europe Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
  • 9.3 Europe Multi-Class Drugs Combination Market Size, By Value (2013-2023)
  • 9.4 Europe NRTI Market Size, By Value (2013-2023)
  • 9.5 Europe NNRTI Market Size, By Value (2013-2023)
  • 9.6 Europe Protease Inhibitors Market Size, By Value (2013-2023)
  • 9.7 Europe Other Antiretroviral Drugs Market Size, By Value (2013-2023)
  • 9.8 Europe Antiretroviral Drugs Market: Country Analysis (Germany, France, U.K, Italy)
    • 9.8.1 Germany Antiretroviral Drugs Market, By Value (2013-2023)
    • 9.8.2 Germany Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)
    • 9.8.4 France Antiretroviral Drugs Market, By Value (2013-2023)
    • 9.8.5 France Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)
    • 9.8.6 UK Antiretroviral Drugs Market, By Value (2013-2023)
    • 9.8.7 UK Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)
    • 9.8.8 Italy Antiretroviral Drugs Market, By Value (2013-2023)
    • 9.8.9 Italy Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

10. APAC Antiretroviral Drugs Market: Growth and Forecast

  • 10.1 APAC Antiretroviral Drugs Market: Segmental Analysis
  • 10.2 APAC Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
    • 10.2.1 APAC Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
    • 10.2.2 APAC Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
  • 10.3 APAC Multi-Class Drugs Combination Market Size, By Value (2013-2023)
  • 10.4 APAC NRTI Market Size, By Value (2013-2023)
  • 10.5 APAC NNRTI Market Size, By Value (2013-2023)
  • 10.6 APAC Protease Inhibitors Market Size, By Value (2013-2023)
  • 10.7 APAC Other Antiretroviral Drugs Market Size, By Value (2013-2023)
  • 10.8 APAC Antiretroviral Drugs Market: Country Analysis (China, Japan, and India)
    • 10.8.1 China Antiretroviral Drugs Market, By Value (2013-2023)
    • 10.8.2 China Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)
    • 10.8.3 Japan Antiretroviral Drugs Market, By Value (2013-2023)
    • 10.8.4 Japan Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)
    • 10.8.5 India Antiretroviral Drugs Market, By Value (2013-2023)
    • 10.8.6 India Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

11. ROW Antiretroviral Drugs Market: Growth and Forecast

  • 11.1 ROW Antiretroviral Drugs Market: Segment Analysis
  • 11.2 ROW Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%)
    • 11.1.1 ROW Antiretroviral Drugs Market Size, By Drug Type, 2017 (%)
    • 11.1.2 ROW Antiretroviral Drugs Market Size, By Drug Type, 2023 (%)
  • 11.3 ROW Multi-Class Drugs Combination Market Size, By Value (2013-2023)
  • 11.4 ROW NRTI Market Size, By Value (2013-2023)
  • 11.5 ROW NNRTI Market Size, By Value (2013-2023)
  • 11.6 ROW Protease Inhibitors Market Size, By Value (2013-2023)
  • 11.7 ROW Other Antiretroviral Drugs Market Size, By Value (2013-2023)
  • 11.8 ROW Antiretroviral Drugs Market: Country Analysis (China, Japan, and India)
    • 11.8.1 South Africa Antiretroviral Drugs Market, By Value (2013-2023)
    • 11.8.2 South Africa Antiretroviral Drugs Market, By Drug Type, By Value (2013-2023)

12. Global Antiretroviral Drugs Market: Market Dynamics

  • 12.1 Global Antiretroviral Drugs Market: Drivers
  • 12.2 Global Antiretroviral Drugs Market: Restrains
  • 12.3 Global Antiretroviral Drugs Market: Trends
  • 12.4 Global Antiretroviral Drugs Market: Product Benchmarking

13. Porter Five Force Analysis

14. SWOT Analysis

15. Company Profiles

  • 15.1 Gilead Sciences
  • 15.2 ViiV Healthcare
  • 15.3 Bristol-Myer Squibb
  • 15.4 AbbVie Inc.
  • 15.5 Boehringer-Ingelheim
  • 15.6 Johnson and Johnson
  • 15.7 Merck & Co.
  • 15.8 CIPLA
  • 17.9 Merck & Co,
Back to Top